Department of Nephrology, The People's Hospital of China Three Gorges University; The First People's Hospital of Yichang, Yichang 443000, Hubei, China.
Department of Urology, The People's Hospital of China Three Gorges University; The First People's Hospital of Yichang, Yichang 443000, Hubei, China.
Biomed Res Int. 2020 Jul 25;2020:5019746. doi: 10.1155/2020/5019746. eCollection 2020.
Papillary renal cell carcinoma (PRCC) is one of the most common histological subtypes of renal cell carcinoma. Type 1 and type 2 PRCC are reported to be clinically and biologically distinct. However, little is known about immune infiltration and the expression patterns of immune-related genes in these two histologic subtypes, thereby limiting the development of immunotherapy for PRCC. Thus, we analyzed the expression of 22 immune cells in type 1 and type 2 PRCC tissues by combining The Cancer Genome Atlas (TCGA) database with the ESTIMATE and CIBERSORT algorithms. Subsequently, we extracted a list of differentially expressed genes associated with the immune microenvironment. Multichip mRNA microarray data sets for PRCC were downloaded from the Gene Expression Omnibus (GEO) to further validate our findings. We found that the immune scores and stromal scores were associated with overall survival in patients with type 2 PRCC rather than type 1 PRCC. Tumor-infiltrating M1 and M2 macrophages could predict the clinical outcome by reflecting the host's immune capacity against type 2 PRCC. Furthermore, CCL19/CCR7, CXCL12/CXCR4, and CCL20/CCR6 were shown to be potential new targets for tumor gene therapy in type 2 PRCC. Our findings provide valuable resources for improving immunotherapy for PRCC.
乳头状肾细胞癌 (PRCC) 是肾细胞癌中最常见的组织学亚型之一。据报道，1 型和 2 型 PRCC 在临床上和生物学上具有明显的差异。然而，对于这两种组织学亚型中的免疫浸润和免疫相关基因的表达模式知之甚少，从而限制了 PRCC 的免疫疗法的发展。因此，我们通过结合癌症基因组图谱 (TCGA) 数据库和 ESTIMATE 和 CIBERSORT 算法，分析了 1 型和 2 型 PRCC 组织中 22 种免疫细胞的表达。随后，我们提取了与免疫微环境相关的差异表达基因列表。从基因表达综合 (GEO) 下载了用于 PRCC 的多芯片 mRNA 微阵列数据集，以进一步验证我们的发现。我们发现，2 型 PRCC 的免疫评分和基质评分与患者的总生存期相关，而与 1 型 PRCC 无关。肿瘤浸润的 M1 和 M2 巨噬细胞可以通过反映宿主对 2 型 PRCC 的免疫能力来预测临床结局。此外，CCL19/CCR7、CXCL12/CXCR4 和 CCL20/CCR6 被证明是 2 型 PRCC 肿瘤基因治疗的潜在新靶点。我们的研究结果为改善 PRCC 的免疫治疗提供了有价值的资源。
